The stock of China Pharma Holdings Inc (CPHI) has gone up by 11.76% for the week, with a -5.00% drop in the past month and a -20.53% drop in the past quarter. The volatility ratio for the week is 17.45%, and the volatility levels for the past 30 days are 13.62% for CPHI. The simple moving average for the last 20 days is 2.52% for CPHI stock, with a simple moving average of -24.20% for the last 200 days.
Is It Worth Investing in China Pharma Holdings Inc (AMEX: CPHI) Right Now?
The 36-month beta value for CPHI is also noteworthy at 0.66. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CPHI is 9.38M, and at present, short sellers hold a 0.50% of that float. The average trading volume of CPHI on December 26, 2024 was 444.90K shares.
CPHI) stock’s latest price update
China Pharma Holdings Inc (AMEX: CPHI)’s stock price has increased by 2.59 compared to its previous closing price of 0.19. However, the company has seen a 11.76% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-18 that HAIKOU, China, Dec. 18, 2024 /PRNewswire/ — China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma”, the “Company” or “We”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced successful completion of all redemptions under its Convertible Promissory Note agreement (the “Convertible Promissory Note”) with Streeterville Capital, LLC as of December 11, 2024. This marks a significant step in strengthening the company’s financial position and reflects its commitment to sound fiscal management.
Analysts’ Opinion of CPHI
Many brokerage firms have already submitted their reports for CPHI stocks, with Rodman & Renshaw repeating the rating for CPHI by listing it as a “Mkt Outperform.” The predicted price for CPHI in the upcoming period, according to Rodman & Renshaw is $6 based on the research report published on January 08, 2010 of the previous year 2010.
CPHI Trading at -7.75% from the 50-Day Moving Average
After a stumble in the market that brought CPHI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.82% of loss for the given period.
Volatility was left at 13.62%, however, over the last 30 days, the volatility rate increased by 17.45%, as shares sank -1.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.83% lower at present.
During the last 5 trading sessions, CPHI rose by +11.07%, which changed the moving average for the period of 200-days by -49.95% in comparison to the 20-day moving average, which settled at $0.1891. In addition, China Pharma Holdings Inc saw -67.95% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CPHI
Current profitability levels for the company are sitting at:
- -0.83 for the present operating margin
- -0.37 for the gross margin
The net margin for China Pharma Holdings Inc stands at -0.86. The total capital return value is set at -0.53. Equity return is now at value -75.07, with -32.92 for asset returns.
Based on China Pharma Holdings Inc (CPHI), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at -0.18. The debt to equity ratio resting at 0.61. The interest coverage ratio of the stock is -26.21.
Currently, EBITDA for the company is 8436.0 with net debt to EBITDA at -1.94. When we switch over and look at the enterprise to sales, we see a ratio of 1.28. The receivables turnover for the company is 13.63for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.79.
Conclusion
In summary, China Pharma Holdings Inc (CPHI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
